These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 6747820)

  • 1. A new statistical procedure for testing equivalence in two-group comparative bioavailability trials.
    Hauck WW; Anderson S
    J Pharmacokinet Biopharm; 1984 Feb; 12(1):83-91. PubMed ID: 6747820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BEQUIV interactive microcomputer program for testing equivalence in two-group comparative bioavailability trials.
    Durisová M; Trnovec T
    Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):129-33. PubMed ID: 3361979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals.
    Steinijans VW; Diletti E
    Eur J Clin Pharmacol; 1983; 24(1):127-36. PubMed ID: 6832195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the analysis and interpretation of bioavailability studies in man.
    Wagner JG
    Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new PK equivalence test for a bridging study.
    Novick SJ; Zhang X; Yang H
    J Biopharm Stat; 2016; 26(5):992-1002. PubMed ID: 26882145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and bioequivalence.
    Skelly JP
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):539-45. PubMed ID: 977792
    [No Abstract]   [Full Text] [Related]  

  • 7. Bioequivalence and intrasubject variability.
    Liu JP
    J Biopharm Stat; 1991; 1(2):205-19. PubMed ID: 1844697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability and pharmacokinetic analysis of drug responding systems.
    Smolen VF
    Annu Rev Pharmacol Toxicol; 1978; 18():495-522. PubMed ID: 348066
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug biodisponibility and generic equivalence (author's transl)].
    Jaminet F
    J Pharm Belg; 1977; 32(4):325-46. PubMed ID: 599404
    [No Abstract]   [Full Text] [Related]  

  • 10. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1992; 30 Suppl 1():S51-8. PubMed ID: 1601532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size determination for bioequivalence assessment by means of confidence intervals.
    Diletti E; Hauschke D; Steinijans VW
    Int J Clin Pharmacol Ther Toxicol; 1991 Jan; 29(1):1-8. PubMed ID: 2004861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bioavailability of drug products and bioequivalence requirements (author's transl)].
    Jaminet F
    J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar.
    Schall R
    Biometrics; 1995 Jun; 51(2):615-26. PubMed ID: 7662849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimum allocation of treatments for Welch's test in equivalence assessment.
    Dette H; Munk A
    Biometrics; 1997 Sep; 53(3):1143-50. PubMed ID: 9333344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of drugs.
    Delaney TP
    Br Med J (Clin Res Ed); 1986 Feb; 292(6517):411. PubMed ID: 3080194
    [No Abstract]   [Full Text] [Related]  

  • 16. Biologic availability and therapeutic equivalence.
    Arnold JD; Sicé J
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):546-9. PubMed ID: 977793
    [No Abstract]   [Full Text] [Related]  

  • 17. The potential clinical significance of differences in bioavailability.
    Hosp Formul; 1976 Sep; 11(9):484, 487-8. PubMed ID: 10316482
    [No Abstract]   [Full Text] [Related]  

  • 18. When are bioavailability studies required? A German proposal.
    Gleiter CH; Klotz U; Kuhlmann J; Blume H; Stanislaus F; Harder S; Paulus H; Poethko-Müller C; Holz-Slomczyk M
    J Clin Pharmacol; 1998 Oct; 38(10):904-11. PubMed ID: 9807970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative bioavailability: what reference?
    Colburn WA; Welling PG
    J Pharm Sci; 1986 Sep; 75(9):921-2. PubMed ID: 3783466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.